Exchange: NYSE·Updated 07:55 PM EDT
ABT logo

ABTAbbott Laboratories

$95.40
$3.22
(3.49%)
Today
Closed $95.40
$0.03
(0.03%)
After Hours
EarningsJul 16
Mkt Cap$166.17B
Vol10.64M
News
all
press releases
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, nutrition, and generic medicines...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.
Zacks
News Placeholder
How Abbott's Largest Segment Is Preparing for the Next Growth Phase
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.
Zacks
News Placeholder
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000
Key PointsDuring times of market turmoil, investors cycle back into defensive, dividend-focused names like Abbott Laboratories...
Nasdaq News: Markets
News Placeholder
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children's Growth
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children's Growth...
Yahoo! Finance: News
News Placeholder
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.
Zacks
News Placeholder
Abbott hosts conference call for second-quarter earnings
Abbott hosts conference call for second-quarter earnings Abbott hosts conference call for second-quarter earnings PR Newswire ABBOTT PARK, Ill., June 25, 2026 ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday...
PR Newswire
News Placeholder
MiniMed Launches Abbott's Instinct Sensors Across European Markets
MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.
Zacks
News Placeholder
How Are Emerging Markets Supporting Abbott's EPD Momentum?
ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.
Zacks
News Placeholder
ALZpath Inks Licensing Deal With Abbott To Expand Blood-Based Alzheimer's Disease Testing
(RTTNews) - Wednesday, ALZpath Inc. announced a licensing agreement with Abbott Laboratories (ABT) to incorporate the company's proprietary phosphorylated Tau 217 antibody into the development of an in vitro diagnostic test for Alzheimer's disease...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.